World's Best Scientists 2026 revealed!
Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
126
Citations
81038
World Ranking
2888
National Ranking
73

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Fortunato Ciardiello is affiliated with the University of Campania "Luigi Vanvitelli" in Italy. Their primary field of study is Medicine, with a focus on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Pathology and Forensic Medicine.

Their research covers a range of topics related to cancer, particularly:

  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Gastric Cancer Management and Outcomes
  • Lung Cancer Research Studies

Ciardiello has published frequently in several major journals, including:

  • Annals of Oncology (38 publications)
  • Journal of Clinical Oncology (21 publications)
  • ESMO Open (16 publications)
  • Cancers (13 publications)
  • Journal of Thoracic Oncology (6 publications)

Recent papers associated with their research include:

  • Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society, 2020, European Journal of Heart Failure
  • Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study, 2021, Journal of Clinical Oncology
  • Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial, 2021, The Lancet Oncology
  • Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology, 2020, European Journal of Heart Failure
  • Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial, 2020, The Lancet Oncology

Frequent co-authors in Ciardiello's research collaborations include:

  • Floriana Morgillo (41 co-authored publications)
  • Teresa Troiani (37 co-authored publications)
  • Josep Tabernero (36 co-authored publications)
  • Carminia Maria Della Corte (36 co-authored publications)
  • Stefania Napolitano (33 co-authored publications)

Best Publications

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Epidermal growth factor-related peptides and their receptors in human malignancies

    David S. Salomon;Ralf Brandt;Fortunato Ciardiello;Nicola Normanno

  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    E. Van Cutsem;A. Cervantes;R. Adam;A. Sobrero

  • EGFR Antagonists in Cancer Treatment

    Fortunato Ciardiello;Giampaolo Tortora

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    H J Schmoll;E Van Cutsem;A Stein;V Valentini

  • Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

    Eric Van Cutsem;Claus Henning Köhne;István Láng;Gunnar Folprecht

  • A NOVEL APPROACH IN THE TREATMENT OF CANCER: TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR

    Fortunato Ciardiello;Giampaolo Tortora

  • Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor

    Ciardiello F;Caputo R;Bianco R;Damiano

  • Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Scott Kopetz;Axel Grothey;Rona Yaeger;Eric Van Cutsem

  • Chronic inflammation and oxidative stress in human carcinogenesis.

    Alessandro Federico;Floriana Morgillo;Concetta Tuccillo;Fortunato Ciardiello

  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial

    Andrea Sartore-Bianchi;Livio Trusolino;Cosimo Martino;Katia Bencardino

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

    Eric Van Cutsem;Heinz Josef Lenz;Claus Henning Köhne;Volker Heinemann

  • Inhibition of Growth Factor Production and Angiogenesis in Human Cancer Cells by ZD1839 (Iressa), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor,

    Fortunato Ciardiello;Rosa Caputo;Roberto Bianco;Vincenzo Damiano

  • Treatment of gastric cancer.

    Michele Orditura;Gennaro Galizia;Vincenzo Sforza;Valentina Gambardella

  • Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

    Sabine Tejpar;Sebastian Stintzing;Fortunato Ciardiello;Josep Tabernero

  • ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

    Francesca Carlomagno;Donata Vitagliano;Teresa Guida;Fortunato Ciardiello

  • Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

    Carsten Bokemeyer;Eric Van Cutsem;Philippe Rougier;Fortunato Ciardiello

  • KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

    Wendy De Roock;Veerle De Vriendt;Nicola Normanno;Fortunato Ciardiello

Frequent Co-Authors

Giampaolo Tortora
Giampaolo Tortora University of Verona
Nicola Normanno
Nicola Normanno Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Stefano Pepe
Stefano Pepe University of Salerno
David S. Salomon
David S. Salomon National Institutes of Health
Salvatore Siena
Salvatore Siena University of Milan
Sabine Tejpar
Sabine Tejpar KU Leuven
Sabino De Placido
Sabino De Placido University of Naples Federico II
Alfredo Falcone
Alfredo Falcone University of Pisa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in healthcare can broaden your career options beyond traditional medical school. For those with non-nursing backgrounds, online direct entry msn programs for non-nursing majors offer a swift route into advanced nursing roles. These programs are designed for individuals who hold a bachelor's degree in another field but wish to pivot into nursing leadership or specialized practice.

Entry requirements can vary between institutions. If you’re concerned about admission competitiveness, you may be interested in learning what is the easiest nursing school to get into, with some schools offering higher acceptance rates or more flexible prerequisites.

Additionally, careers like medical billing and coding provide a different route into healthcare administration. Many online programs are available, offering flexibility as well as support for students wondering can you get financial aid for medical billing and coding.

Finally, some prospective nurses may be anxious about standardized testing. There are nursing schools that don't require teas or hesi as admission requirements, making the process less intimidating and more accessible for a wider range of students.

Best Scientists Citing Fortunato Ciardiello

Trending Scientists